Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now? - Yahoo Finance

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?  Yahoo Finance

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's ...

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan  CNBC

Pfizer CEO Albert Bourla Discusses Balancing Medicine Accessibility with Shareholder Returns in R...

Pfizer CEO Albert Bourla Discusses Balancing Medicine Accessibility with Shareholder Returns in Reuters Interview  geneonline.com

Travis Kelce's reported big money Pfizer deal sparks mixed reactions from fans - MARCA

Travis Kelce's reported big money Pfizer deal sparks mixed reactions from fans  MARCA

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600...

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer  Pfizer

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on 'fabulous' bispecific...

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on 'fabulous' bispecific  Fierce Biotech

Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out (NYSE:PFE) - Seeking Alpha

Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out (NYSE:PFE)  Seeking Alpha

Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others...

Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others  Fierce Pharma

Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential - 24/7 Wall St.

Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential  24/7 Wall St.

Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq

Should Value Investors Buy Pfizer (PFE) Stock?  Nasdaq

Pfizer Enters into Exclusive Licensing Agreement with 3SBio - Business Wire

Pfizer Enters into Exclusive Licensing Agreement with 3SBio  Business Wire

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth? - Yahoo Finance

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?  Yahoo Finance

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormo...

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer  Pfizer

Pfizer: An Offensive Play For A Bear Market (NYSE:PFE) - Seeking Alpha

Pfizer: An Offensive Play For A Bear Market (NYSE:PFE)  Seeking Alpha

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting cl...

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer  CNBC

Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?  Yahoo Finance

Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer

Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility  Pfizer

The past three years for Pfizer (NYSE:PFE) investors has not been profitable - Yahoo Finance

The past three years for Pfizer (NYSE:PFE) investors has not been profitable  Yahoo Finance

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer  Pfizer

Pfizer Awarded Diamond Resiliency Badge for Supply Chain Excellence - Pfizer

Pfizer Awarded Diamond Resiliency Badge for Supply Chain Excellence  Pfizer

Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging...

Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging  simplywall.st

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression  Reuters

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting - Pfizer

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting  Pfizer

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-...

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707  geneonline.com

NATO for medicines? Pfizer CEO calls for higher drug spending outside US amid Trump’s MFN pricing...

NATO for medicines? Pfizer CEO calls for higher drug spending outside US amid Trump’s MFN pricing push  Fierce Pharma

“Taylor swift’s b*tch”: Travis Kelce ruthlessly accused of using his girlfriend’s fame to trade N...

“Taylor swift’s b*tch”: Travis Kelce ruthlessly accused of using his girlfriend’s fame to trade NFL legac  Times of India

Health Answers by Pfizer Wins Webby’s People’s Voice Award - Pfizer

Health Answers by Pfizer Wins Webby’s People’s Voice Award  Pfizer

Join Pfizer in the Fight Against Cancer - Pfizer

Join Pfizer in the Fight Against Cancer  Pfizer

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody...

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707  geneonline.com

175 Days of Good - Pfizer

175 Days of Good  Pfizer

Pfizer CEO Albert Bourla Discusses Balancing Drug Affordability with Shareholder Profits in Reute...

Pfizer CEO Albert Bourla Discusses Balancing Drug Affordability with Shareholder Profits in Reuters Interview  geneonline.com

Pfizer buys into PD-1/VEGF competition with 3SBio deal - BioPharma Dive

Pfizer buys into PD-1/VEGF competition with 3SBio deal  BioPharma Dive

Pfizer Recognized as “2024 Corporate Partner of the Year” by American Cancer Society - Pfizer

Pfizer Recognized as “2024 Corporate Partner of the Year” by American Cancer Society  Pfizer

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance - Business Wire

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance  Business Wire

Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN En...

Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud  Fierce Pharma

United by Our Unique and Personal Connections to Cancer - Pfizer

United by Our Unique and Personal Connections to Cancer  Pfizer

VA study: Pfizer COVID booster 68% effective against hospitalization - CIDRAP

VA study: Pfizer COVID booster 68% effective against hospitalization  CIDRAP

Comparing the COVID-19 Vaccines: How Are They Different? - Yale Medicine

Comparing the COVID-19 Vaccines: How Are They Different?  Yale Medicine

Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC

Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland  CNBC

March Social Media Round-Up—Annual Review, Fast Company, and More - Pfizer

March Social Media Round-Up—Annual Review, Fast Company, and More  Pfizer

Pfizer Hosts SPH Practicum Students for Second Summer - Boston University

Pfizer Hosts SPH Practicum Students for Second Summer  Boston University

Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity - STAT

Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity  STAT

Pfizer Earnings: Expected Sales Decline Met With Solid Bottom-Line Growth From Cost Savings - Mor...

Pfizer Earnings: Expected Sales Decline Met With Solid Bottom-Line Growth From Cost Savings  Morningstar

Pfizer and Our CEO Albert Bourla Recognized by TIME, Fortune - Pfizer

Pfizer and Our CEO Albert Bourla Recognized by TIME, Fortune  Pfizer

Pfizer revises its DEI webpage to emphasize importance of ‘merit’ - STAT

Pfizer revises its DEI webpage to emphasize importance of ‘merit’  STAT

Pfizer’s 4th Latino Summit Champions Latino Representation - Pfizer

Pfizer’s 4th Latino Summit Champions Latino Representation  Pfizer

Living with Colon Cancer: A Pfizer Colleague’s Story - Pfizer

Living with Colon Cancer: A Pfizer Colleague’s Story  Pfizer

Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech

Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity  BioWorld MedTech

Pfizer adds J&J, BMS vet James List to its executive roster as new chief internal medicine office...

Pfizer adds J&J, BMS vet James List to its executive roster as new chief internal medicine officer  Fierce Biotech

Pfizer could use existing US manufacturing to counter potential tariff hit - Reuters

Pfizer could use existing US manufacturing to counter potential tariff hit  Reuters

Pfizer ends development of weight-loss pill danuglipron - Reuters

Pfizer ends development of weight-loss pill danuglipron  Reuters

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-...

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707  geneonline.com

PAHO, Argentina, Pfizer, and Sinergium drive local production of 20-valent pneumococcal vaccine f...

PAHO, Argentina, Pfizer, and Sinergium drive local production of 20-valent pneumococcal vaccine for Latin America and the Caribbean  Pan American Health Organization (PAHO)

US House panel seeks information from Pfizer over alleged COVID vaccine delay - Reuters

US House panel seeks information from Pfizer over alleged COVID vaccine delay  Reuters

UC San Diego Moores Cancer Center Receives $1M Donation from Pfizer for Early Cancer Detection - ...

UC San Diego Moores Cancer Center Receives $1M Donation from Pfizer for Early Cancer Detection  UC San Diego Today

Option traders moderately bearish in Pfizer with shares down 1.0% - TipRanks

Option traders moderately bearish in Pfizer with shares down 1.0%  TipRanks

Novavax says its COVID vaccine produces fewer, milder reactions than Pfizer version - CIDRAP

Novavax says its COVID vaccine produces fewer, milder reactions than Pfizer version  CIDRAP

Pfizer stops commercialization of hemophilia gene therapy Beqvez - Reuters

Pfizer stops commercialization of hemophilia gene therapy Beqvez  Reuters

Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 -...

Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19  Nature

Pfizer ends development of potential pill obesity treatment - CNN

Pfizer ends development of potential pill obesity treatment  CNN

Pfizer School of Science Marks Two Years of Impacting Communities - Pfizer

Pfizer School of Science Marks Two Years of Impacting Communities  Pfizer

In Search of a New Hemophilia Treatment - Pfizer

In Search of a New Hemophilia Treatment  Pfizer

Pfizer sells entire Haleon stake for $3.24 billion - Reuters

Pfizer sells entire Haleon stake for $3.24 billion  Reuters

Pfizer Looks Back at 2024 in the Annual Review - Pfizer

Pfizer Looks Back at 2024 in the Annual Review  Pfizer

Pfizer School of Science Mobile Experience: Inspiring the Next Generation of Innovators - Pfizer

Pfizer School of Science Mobile Experience: Inspiring the Next Generation of Innovators  Pfizer

Proxy adviser ISS recommends against Pfizer executive pay proposal - Reuters

Proxy adviser ISS recommends against Pfizer executive pay proposal  Reuters

Pfizer CEO Albert Bourla Discusses Balancing Innovation and Global Medicine Accessibility in Reut...

Pfizer CEO Albert Bourla Discusses Balancing Innovation and Global Medicine Accessibility in Reuters Interview  geneonline.com

Pfizer Takes Over SXSW’s Podcasting Lounge for the Second Year in a Row - Pfizer

Pfizer Takes Over SXSW’s Podcasting Lounge for the Second Year in a Row  Pfizer

With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer f...

With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field  Fierce Biotech

Pfizer leans on cost cuts to offset falling revenue - Reuters

Pfizer leans on cost cuts to offset falling revenue  Reuters

Pfizer to pay $59.7 million over kickbacks for migraine drug - Reuters

Pfizer to pay $59.7 million over kickbacks for migraine drug  Reuters

Pfizer scraps daily weight loss pill after liver injury in one patient - CNBC

Pfizer scraps daily weight loss pill after liver injury in one patient  CNBC

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in...

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)  Business Wire

Transcript : Pfizer Inc. - Special Call - MarketScreener

Transcript : Pfizer Inc. - Special Call  MarketScreener

David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lun...

David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field  Fierce Pharma

What Investors Are Missing about Pfizer and Merck - Yale Insights

What Investors Are Missing about Pfizer and Merck  Yale Insights

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck - Fi...

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck  Fierce Biotech

Patrizia Cavazzoni, former head of FDA’s drug center, joins Pfizer as chief medical officer - STAT

Patrizia Cavazzoni, former head of FDA’s drug center, joins Pfizer as chief medical officer  STAT

Harnessing the Power of AI to Detect ATTR-CM - Pfizer

Harnessing the Power of AI to Detect ATTR-CM  Pfizer

Pfizer must face lawsuit over diversity fellowship program, US court rules - Reuters

Pfizer must face lawsuit over diversity fellowship program, US court rules  Reuters

Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal - Reuters

Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal  Reuters

Pfizer’s Annual DEI Summit Focuses on Inclusion and Connection - Pfizer

Pfizer’s Annual DEI Summit Focuses on Inclusion and Connection  Pfizer

GSK resolves patent lawsuit against Pfizer over RSV vaccines - Reuters

GSK resolves patent lawsuit against Pfizer over RSV vaccines  Reuters

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance - Business Wire

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance  Business Wire

Pfizer Works to Address Inequities in IBD Care - Pfizer

Pfizer Works to Address Inequities in IBD Care  Pfizer

Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan - Fierce Biotech

Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan  Fierce Biotech

Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B - Fierce Pharma

Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B  Fierce Pharma

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D - CNBC

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D  CNBC

Pfizer stops selling hemophilia gene therapy, citing weak demand - BioPharma Dive

Pfizer stops selling hemophilia gene therapy, citing weak demand  BioPharma Dive

Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - gene...

Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707  geneonline.com

Pfizer names former FDA director as chief medical officer - Reuters

Pfizer names former FDA director as chief medical officer  Reuters

Pfizer reports mixed results in first quarter earnings, reiterates 2025 outlook - Yahoo Finance

Pfizer reports mixed results in first quarter earnings, reiterates 2025 outlook  Yahoo Finance

Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio - Fierce Pharma

Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio  Fierce Pharma

Pfizer Earnings: After Solid Results, Reaffirmed 2025 Guidance - Morningstar

Pfizer Earnings: After Solid Results, Reaffirmed 2025 Guidance  Morningstar

Pfizer going 'all in' on obesity drug development, CEO Bourla says - Reuters

Pfizer going 'all in' on obesity drug development, CEO Bourla says  Reuters

Top Pfizer Shareholders - Investopedia

Top Pfizer Shareholders  Investopedia

Pfizer to halt development of closely watched weight-loss drug - Financial Times

Pfizer to halt development of closely watched weight-loss drug  Financial Times

Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review - BioSpace

Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review  BioSpace

Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody - BioSpace

Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody  BioSpace

Pfizer exits NC jobs deal in Sanford as drugmaker announces larger cost cuts - Raleigh News & Obs...

Pfizer exits NC jobs deal in Sanford as drugmaker announces larger cost cuts  Raleigh News & Observer